GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Greenwich Lifesciences GLSI · USD

Health Care · US listing · 🇺🇸 United States

Compare

16.52

+8.90%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Greenwich Lifesciences

From its filings with the US Securities and Exchange Commission

SEC filings

Greenwich Lifesciences is based in Stafford, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GLSI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $19.4m. At that date it held total assets of $6.2m and shareholders' equity of $353,217.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Sept 2020
Employees
4
Head office
3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. David McwilliamsIndependent Chairman of the Board, since 2009$255,818
  • Mr. Snehal PatelChief Executive Officer, Chief Financial Officer, Director, since 2010$6.2m
  • Dr. Jaye ThompsonVice President - Clinical & Regulatory Affairs
  • Dr. F. Joseph DaughertyChief Medical Officer, Director, since 2019
  • Mr. Kenneth HallockIndependent Director$170,650
  • Mr. Eric RotheIndependent Director, since 2006$170,650

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
17
Environment
18
Social
24
Governance
10
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Greenwich Lifesciences Inc develops GP2 immunotherapy for breast cancer recurrence prevention.
  • GP2 is a 9 amino acid peptide targeting HER2/neu protein in cancer cells.
  • The company focuses on immunotherapy to selectively attack cancer cells without harming normal cells.

Weaknesses

  • Greenwich Lifesciences has only 4 employees including full-time staff.
  • The company went public on 25 September 2020 with limited resources.
  • GP2 treatment requires mixing at the time of administration, increasing complexity.

Opportunities

  • The US market offers significant potential for breast cancer immunotherapy treatments.
  • GP2 could expand to other HER2/neu expressing cancers beyond breast cancer.
  • The growing focus on targeted cancer therapies presents new market opportunities.

Threats

  • Breast cancer immunotherapy faces competition from established treatments in the US market.
  • Regulatory approval delays could impact GP2's market entry timeline.
  • The biotechnology sector has high failure rates for new immunotherapies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.